SCHEMBL3015958

SCHEMBL3015958

Cc1cc(C)c(Cc2csc(N3CCC(S(=O)(=O)c4ccc(Cl)cc4)CC3)n2)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 7/20 0.37
DRD2 P14416 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
KCNH2 Q12809 1/20 0.37
DNM1L O00429 6/20 0.37
GBA1 P04062 1/20 0.37
LMNA P02545 6/20 0.36
TP53 P04637 3/20 0.36
NPSR1 Q6W5P4 2/20 0.35
TSHR P16473 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
POLB P06746 2/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
HPGD P15428 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015515 0.93 GBA1 (0.42) KMT2AMEN1MAPTDNM1LGBA1
SCHEMBL3015893 0.92 DNM1L (0.36) KMT2AMEN1MAPTDNM1LGBA1
SCHEMBL3023007 0.91 MEN1 (0.38) KMT2AMEN1MAPTDRD2HTR2A
SCHEMBL3002912 0.91 LMNA (0.36) KMT2AMAPTDNM1LGBA1LMNA
SCHEMBL3007065 0.90 SMN1; SMN2 (0.39) KMT2AMAPTDRD2HTR2AHTR2C
SCHEMBL3020585 0.90 DNM1L (0.37) KMT2AMEN1MAPTDNM1LGBA1
SCHEMBL3012839 0.90 DNM1L (0.35) KMT2AMEN1MAPTDRD2HTR2A
SCHEMBL3008159 0.90 RAB9A (0.39) MAPTHTR2AHTR2CDNM1LGBA1
SCHEMBL3020257 0.89 MAPT (0.38) KMT2AMEN1MAPTDRD2HTR2A
SCHEMBL3022020 0.89 DNM1L (0.36) KMT2AMAPTDNM1LGBA1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KMT2A 2680/4885MEN1 454/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.